Skip to main content
Log in

Dissemination of cephalosporin-resistantSerratia marcescens strains producing a plasmidic SHV type beta-lactamase in Greek hospitals

  • Notes
  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

Abstract

The resistance to third generation cephalosporins in nineSerratia marcescens strains isolated in Greek hospitals was studied. Eight of the strains transferred resistance toEscherichia coli by means of large plasmids that encoded for an extended-spectrum β-lactamase. Hybridization, isoelectric focusing and hydrolysis studies showed that the enzyme resembled the SHV-5 β-lactamase. In the eight isolates that possessed the SHV type enzyme, cephalosporinase expression was inducible, whereas the remaining strain was a cephalosporinase hyperproducing strain. Introduction of a plasmid coding for the regulatoryampD gene in the latter strain eliminated β-lactamase production and rendered the strain susceptible to cephalosporins.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Montanaro D, Grasso GM, Annino I, De Ruggiero N, Scarcella A, Schioppa F: Epidemiological and bacteriological investigation of aSerratia marcescens epidemic in a nursery and in a neonatal intensive care unit. Journal of Hygiene 1984, 93: 67–78.

    PubMed  Google Scholar 

  2. Stamm WE, Weinstein RA, Dixon RE: Comparison of endemic and epidemic nosocomial infections. American Journal of Medicine 1981, 70: 230–234.

    Article  Google Scholar 

  3. Traub WH, Bauer D: Outer membrane alterations inSerratia marcescens resistant against aminoglycoside and beta-lactam antibiotics. Chemotherapy 1987, 33: 172–176.

    PubMed  Google Scholar 

  4. Hechler U, van den Weghe M, Martin HH, Frere JM: Overproduced β-lactamase and the outer membrane barrier as resistance factors inSerratia marcescens highly resistant to β-lactamase-stable β-lactam antibiotics. Journal of General Microbiology 1989, 135: 1275–1290.

    PubMed  Google Scholar 

  5. Sanders CC, Watanakunakorn C: Emergence of resistance to β-lactams, aminoglycosides, and quinolones during combination therapy for infection due toSerratia marcescens. Journal of Infectious Diseases 1986, 153: 617–619.

    PubMed  Google Scholar 

  6. Payne DJ, Marriot MS, Amyes SGB: Plasmid mediated ceftazidime resistance identified in a strain ofSerratia marcescens isolated in Belgium. Journal of Antimicrobial Chemotherapy 1992, 27: 689–692.

    Google Scholar 

  7. Mercier J, Levesque RC: Cloning of SHV-2, OHIO-1, and OXA-6 β-lactamases and cloning and sequencing of SHV-1 β-lactamase. Antimicrobial Agents and Chemotherapy 1990, 34: 1577–1583.

    PubMed  Google Scholar 

  8. Vatopoulos AC, Philippon A, Tzouvelekis LS, Komninou Z, Legakis NJ: Prevalence of a transferable SHV-5 type β-lactamase in clinical isolates ofKlebsiella pneumoniae andEscherichia coli in Greece. Journal of Antimicrobial Chemotherapy 1990, 26: 635–648.

    PubMed  Google Scholar 

  9. Honore N, Nicolas MH, Cole ST: Inducible cephalosporinase production in clinical isolates ofEnterobacter cloacae is controlled by a regulatory gene that has been deleted fromEscherichia coli. EMBO Journal 1986, 5: 3709–3714.

    PubMed  Google Scholar 

  10. National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard M7-T2. NCCLS, Villianova, PA, 1988.

    Google Scholar 

  11. Jarlier V, Nicolas MH, Fournier G, Philippon A: Extended broad-spectrum β-lactamases conferring transferable resistance to newer β-lactam agents inEnterobacteriaceae: hospital prevalence and susceptibility patterns. Reviews of Infectious Diseases 1988, 10: 867–878.

    PubMed  Google Scholar 

  12. Sambrook J, Fritsch EF, Maniatis T: Molecular cloning: a laboratory manual. Cold Spring Harbor Press, Cold Spring Harbor, NY, 1989, p. 74.

    Google Scholar 

  13. Portnoy DA, Mosely SL, Falkow S: Characterization of plasmid and plasmid associated determinants ofYersinia enterocolitica pathogenesis. Infection and Immunity 1981, 31: 775–782.

    PubMed  Google Scholar 

  14. Tzelepi E, Tzouvelekis LS, Vatopoulos AC, Mentis AF, Tsakris A, Legakis NJ: High prevalence of stably derepressed class-I β-lactamase expression in multiresistant clinical isolates ofEnterobacter cloacae from Greek hospitals. Journal of Medical Microbiology 1992, 37: 91–95.

    PubMed  Google Scholar 

  15. O'Callaghan CH, Muggleton PW, Ross GW: Effects of β-lactamases from gram-negative organisms on cephalosporins and penicillins. In: Hobby GL (ed): Antimicrobial agents and chemotherapy. American Society for Microbiology, Bethesda, 1968, p. 57–63.

    Google Scholar 

  16. Tzouvelekis LS, Tzelepi E, Mentis AF, Tsakris A: Identification of a novel plasmid-mediated β-lactamase with chromosomal cephalosporinase characteristics fromKlebsiella pneumoniae. Journal of Antimicrobial Chemotherapy 1993, 31: 645–654.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gianneli, D., Tzelepi, E., Tzouvelekis, L.S. et al. Dissemination of cephalosporin-resistantSerratia marcescens strains producing a plasmidic SHV type beta-lactamase in Greek hospitals. Eur. J. Clin. Microbiol. Infect. Dis. 13, 764–767 (1994). https://doi.org/10.1007/BF02276063

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02276063

Keywords

Navigation